Zhu Liuluan, Zhou Yanxi, Li Rui, Deng Shuwei
Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Beijing Institute of Infectious Diseases, Beijing 100015, China.
Autophagy Rep. 2022 Sep 4;1(1):389-392. doi: 10.1080/27694127.2022.2119513. eCollection 2022.
The pathogenesis of liver fibrosis in nonalcoholic fatty liver disease (NAFLD) remains unclear and the effective treatments have not been explored yet. The activation of hepatic stellate cells (HSCs) is the most critical factor in the progression of liver fibrosis. Macroautophagy/autophagy has recently been identified as a new mechanism to regulate HSC activation. In a recent study, we found that type 2 (M2) macrophages promote HSC autophagy by secreting prostaglandin E2 (PGE2) to bind its receptor PTGER4/EP4 on HSCs, consequently activating the MAPK/ERK pathway to promote autophagy and activation of HSCs. A specific PGE2-PTGER4 antagonist, E7046, significantly inhibits HSC autophagy and improves liver fibrosis and histopathology in NAFLD mice. Our findings provide novel mechanistic insights into liver fibrosis and suggest E7046 as a promising therapy to prevent NASH progression.
非酒精性脂肪性肝病(NAFLD)中肝纤维化的发病机制仍不清楚,尚未探索出有效的治疗方法。肝星状细胞(HSCs)的激活是肝纤维化进展中最关键的因素。巨自噬/自噬最近被确定为一种调节肝星状细胞激活的新机制。在最近的一项研究中,我们发现2型(M2)巨噬细胞通过分泌前列腺素E2(PGE2)与肝星状细胞上的受体PTGER4/EP4结合,从而促进肝星状细胞自噬,进而激活MAPK/ERK途径,促进自噬和肝星状细胞的激活。一种特异性PGE2-PTGER4拮抗剂E7046可显著抑制NAFLD小鼠肝星状细胞自噬,并改善肝纤维化和组织病理学。我们的研究结果为肝纤维化提供了新的机制见解,并表明E7046作为一种有前景的治疗方法可预防NASH进展。